The Dana-Farber Cancer Institute (DFCI) and its affiliates will enter patients onto POG studies. Specific contributions from DFCI are focused on protocol development and group leadership. Dr. Howard J. Weinstein is the Chairman of the Myeloid Disease Committee as well as an active leading member of the Bone Marrow Transplant Core Committee. He has committed the Bone Marrow Transplant Unit of The Children's Hospital in Boston and the facilities of the Dana-Farber Cancer Institute to POG transplant protocols. Dr. Holcombe Grier is the Principal Investigator of the POG/CCSG National Ewing Sarcoma protocol, as well as an active member of the Late Effects Committee. Dr. Allen Goorin is the Principal Investigator of the primary osteogenic sarcoma protocol. Dr. Stephen E. Sallan and Dr. Amy Billett are active members of the POG Lymphoid Relapse Committee and Dr. Billett has recently written a POG relapse ALL protocol. Dr. Nancy Tarbell, Radiation Therapist, has been active in the Radiation Therapy Discipline Committee, especially in protocols pertaining to the treatment of bone tumors and brain tumors. She is a co-Principal Investigator of the Ewing's sarcoma protocol and the brain stem glioma protocol for the POG, and Dr. Tarbell was elected as the radiation therapy representative to the Bone Marrow Transplant Core Committee, and also serves at the radiation therapy representative for the non-Hodgkin's Core Committee. Dr. Andrea Patenaude, staff psychologist, is a member of the Psychology Committee and the Bone Marrow Transplant Core Committee, and a co-PI of a protocol for evaluation of psychological survival of AML patients. Dr. Gebhardt is an orthopedic surgeon who is a co-PI of the osteogenic sarcoma protocol and Ewing's sarcoma protocol, and an active member of the Bone Tumor Committee. In summary, the majority of DFCI physicians have taken major leadership roles in POG programs, attended POG meetings, as well as extra committee meetings through the years, and the DFCI has contributed significant numbers of patients to POG treatment protocols.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Ravindranath, Y; Chang, M; Steuber, C P et al. (2005) Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19:2101-16
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Goorin, Allen M; Schwartzentruber, Douglas J; Devidas, Meenakshi et al. (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574-80
Goorin, Allen M; Harris, Michael B; Bernstein, Mark et al. (2002) Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 20:426-33
Lacayo, N J; Lum, B L; Becton, D L et al. (2002) Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 16:920-7
Berg, S L; Blaney, S M; Sullivan, J et al. (2000) Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 22:506-9
Mahoney Jr, D H; Cohen, M E; Friedman, H S et al. (2000) Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro Oncol 2:213-20
Parsons, S K; Mayer, D K; Alexander, S W et al. (2000) Growth factor practice patterns among pediatric oncologists: results of a 1998 Pediatric Oncology Group Survey. Economic Evaluation Working Group the Pediatric Oncology Group. J Pediatr Hematol Oncol 22:227-41
Thomas, P R; Deutsch, M; Kepner, J L et al. (2000) Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18:3004-11
Cushing, B; Giller, R; Ablin, A et al. (1999) Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group. Am J Obstet Gynecol 181:353-8

Showing the most recent 10 out of 21 publications